Efficacy of topiramate in reducing second‐generation antipsychotic‐associated weight gain among children: A systematic review and meta‐analysis
Authors' conclusion
This meta-analysis suggests that topiramate is an effective and safe option for mitigating SGA-associated weight gain in children.
Study context
- Population
- Children aged 4–18 years on second-generation antipsychotics (second-generation antipsychotic (SGA)); 43.9% female; mean [SD] age 11.9 [3.5] years
- Participants
- 139 children5 RCTs
- Comparison
- Adjunctive topiramate vs placebo with SGA treatment
- Outcome
- Changes in body weight and body mass index (BMI)
Methodological detailsSearched PubMed, Embase, PsychNet and Web of Science to 12 February 2024
- Searched PubMed, Embase, PsychNet and Web of Science to 12 February 2024
Pooled result
As reported in the abstract
Topiramate vs PlaceboMD, kg (95% CI)P value
Weight gain; I2 = 86.7%
−2.80(−5.28 to −0.31)
P = 0.037Topiramate vs PlaceboSMD (95% CI)P value
Weight gain; I2 = 31.7%
−1.33(−2.14 to −0.51)
P = 0.014BMI change; I2 = 0%
−1.90(−3.09 to −0.70)
P = 0.02Further pooled results
Metabolic parameters (TG, total cholesterol, LDL, HDL, glucose)
- No significant differences
Safety
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| SedationI2 = 0% | 0.19 (0.11–0.32) | P < 0.01 | |
| 0.10.31310Odds ratio (log scale) |
Dropouts and other side effects
- No significant differences in dropouts and any other side effects
- No included study reported cognitive side effects
Original publication
Efficacy of topiramate in reducing second‐generation antipsychotic‐associated weight gain among children: A systematic review and meta‐analysis. Diabetes Obes Metab. Published 13 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →